Bright Minds Biosciences (DRUG) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T16:02:24.939Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:02:24.939Z.

Quote observation: 2026-10-06T15:59:42.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -28,492,622.96452
Quote market capitalization: 477,270,857
Total debt · period ending 2026-06-30: 46,249.984
Cash · period ending 2026-06-30: 216,944,010.62399998

FMP input reference: 6caa0376099c5ebdf209f9b018955c4d65987c3db8176dc1b5ff0a1c5aca19bf

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

DRUG EBITDA Yield Metrics

EBITDA YIELD

N/A

DRUG Competitors' EBITDA Yield

DRUG

Bright Minds Biosciences Inc.

Current

Market Cap

$477.27M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTNM

Contineum Therapeutics, Inc.

vs DRUG

Market Cap

$474.22M

EBITDA Yield

N/A

TTM Avg

25.96%

3Y Avg

19.61%

5Y Avg

19.61%

CERS

Cerus Corporation

vs DRUG

Market Cap

$475.46M

EBITDA Yield

0.01%

TTM Avg

0.01%

3Y Avg

0.01%

5Y Avg

0.01%

ARVN

Arvinas, Inc.

vs DRUG

Market Cap

$479.06M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KMDA

Kamada Ltd.

vs DRUG

Market Cap

$472.48M

EBITDA Yield

9.48%

TTM Avg

10.23%

3Y Avg

10.38%

5Y Avg

8.34%

PBYI

Puma Biotechnology, Inc.

vs DRUG

Market Cap

$486.85M

EBITDA Yield

9.54%

TTM Avg

13.75%

3Y Avg

18.95%

5Y Avg

18.84%

EOLS

Evolus, Inc.

vs DRUG

Market Cap

$491.28M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NRC

NRC Health

vs DRUG

Market Cap

$462.12M

EBITDA Yield

4.26%

TTM Avg

6.53%

3Y Avg

7.37%

5Y Avg

6.54%

OCS

Oculis Holding AG

vs DRUG

Market Cap

$498.55M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DMAC

DiaMedica Therapeutics Inc.

vs DRUG

Market Cap

$451.59M

EBITDA Yield

N/A

TTM Avg

8.61%

3Y Avg

13.81%

5Y Avg

19.64%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Bright Minds Biosciences Inc. (DRUG)	$477.27M	N/A	N/A	N/A	N/A
Contineum Therapeutics, Inc. (CTNM)vs ›	$474.22M	N/A	25.96%	19.61%	19.61%
Cerus Corporation (CERS)vs ›	$475.46M	0.01%	0.01%	0.01%	0.01%
Arvinas, Inc. (ARVN)vs ›	$479.06M	N/A	N/A	N/A	N/A
Kamada Ltd. (KMDA)vs ›	$472.48M	9.48%	10.23%	10.38%	8.34%
Puma Biotechnology, Inc. (PBYI)vs ›	$486.85M	9.54%	13.75%	18.95%	18.84%
Evolus, Inc. (EOLS)vs ›	$491.28M	N/A	N/A	N/A	N/A
NRC Health (NRC)vs ›	$462.12M	4.26%	6.53%	7.37%	6.54%
Oculis Holding AG (OCS)vs ›	$498.55M	N/A	N/A	N/A	N/A
DiaMedica Therapeutics Inc. (DMAC)vs ›	$451.59M	N/A	8.61%	13.81%	19.64%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

DRUG EBITDA Yield Metrics

DRUG Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics